Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

2.

Stability of an Extemporaneously Compounded Oral Suspension of Bosentan.

Malik A, Gorman G, Coward L, Arnold JJ.

Hosp Pharm. 2016 May;51(5):389-95. doi: 10.1310/hpj5105-389.

3.

Small Molecules Revealed in a Screen Targeting Epithelial Scattering Are Inhibitors of Microtubule Polymerization.

Hoj TH, Robinson RJ, Burton JC, Densley-Ure RA, Olson TV, Williams LK, Coward L, Gorman G, Hansen MD.

J Biomol Screen. 2016 Aug;21(7):671-9. doi: 10.1177/1087057116651850. Epub 2016 May 31.

PMID:
27245142
4.

Using the Change Manager Model for the Hippocampal System to Predict Connectivity and Neurophysiological Parameters in the Perirhinal Cortex.

Coward LA, Gedeon TD.

Comput Intell Neurosci. 2016;2016:8625875. doi: 10.1155/2016/8625875. Epub 2015 Dec 27. Review.

5.

Incorporation of hands-on sterile technique instruction in an introductory pharmacy practice experience.

Cretton-Scott E, Cruthirds D, Coward L.

Am J Pharm Educ. 2015 Mar 25;79(2):28. doi: 10.5688/ajpe79228.

6.

In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism.

Grappe F, Nance G, Coward L, Gorman G.

Drug Metabol Drug Interact. 2014;29(4):269-79. doi: 10.1515/dmdi-2014-0017.

PMID:
25153228
7.

Effects of herbal supplements on the bioactivation of chemotherapeutic agents.

Gorman GS, Coward L, Darby A, Rasberry B.

J Pharm Pharmacol. 2013 Jul;65(7):1014-25. doi: 10.1111/jphp.12055. Epub 2013 Mar 25.

PMID:
23738729
8.

An integrated alcohol abuse and medical treatment model for patients with hepatitis C.

Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, Bixby P, Muir AJ.

Dig Dis Sci. 2012 Apr;57(4):1083-91. doi: 10.1007/s10620-011-1976-4. Epub 2011 Dec 2.

9.

Locked in and out: a case of emerging basilar artery obstruction secondary to vertebral artery dissection thrombolysed with intravenous rt-PA.

Al-Raweshidy YH, Sinha DM, Coward LJ, Guyler PC, O'Brien A.

BMJ Case Rep. 2011 May 12;2011. pii: bcr1220103584. doi: 10.1136/bcr.12.2010.3584.

10.

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.

Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):513-24. doi: 10.1007/s00280-010-1518-3. Epub 2010 Nov 18.

PMID:
21085965
11.

A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.

Gorman GS, Coward LU, Freeman L, Noker PE, Beattie CW, Jia L.

J Pharm Biomed Anal. 2010 Dec 1;53(4):991-6. doi: 10.1016/j.jpba.2010.06.006. Epub 2010 Jun 30.

12.

The hippocampal system as the cortical resource manager: a model connecting psychology, anatomy and physiology.

Coward LA.

Adv Exp Med Biol. 2010;657:315-64. doi: 10.1007/978-0-387-79100-5_18.

PMID:
20020356
13.

In-vitro and in-vivo metabolic studies of the candidate chemopreventative pentamethylchromanol using liquid chromatography/tandem mass spectrometry.

Gorman GS, Coward L, Kerstner-Wood C, Freeman L, Hebert CD, Kapetanovic IM.

J Pharm Pharmacol. 2009 Oct;61(10):1309-18. doi: 10.1211/jpp/61.10.0006.

PMID:
19814862
14.

A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y, Sani B, Hobrath JV, Maxuitenko YY, Reynolds RC.

Cancer Prev Res (Phila). 2009 Jun;2(6):572-80. doi: 10.1158/1940-6207.CAPR-09-0001. Epub 2009 May 26.

15.

Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate.

Jia L, Noker PE, Piazza GA, Leuschner C, Hansel W, Gorman GS, Coward LU, Tomaszewski J.

J Pharm Pharmacol. 2008 Nov;60(11):1441-8. doi: 10.1211/jpp.60.11.0004.

16.

Hierarchical approaches to understanding consciousness.

Coward LA, Sun R.

Neural Netw. 2007 Nov;20(9):947-54. Epub 2007 Sep 8.

PMID:
17890054
17.

In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid.

Gorman GS, Coward L, Kerstner-Wood C, Cork L, Kapetanovic IM, Brouillette WJ, Muccio DD.

Drug Metab Dispos. 2007 Jul;35(7):1157-64. Epub 2007 Apr 19.

PMID:
17446266
18.
19.

Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.

Jia L, Coward LC, Kerstner-Wood CD, Cork RL, Gorman GS, Noker PE, Kitada S, Pellecchia M, Reed JC.

Cancer Chemother Pharmacol. 2008 Jan;61(1):63-73. Epub 2007 Mar 14.

PMID:
17356822
20.

Quantitative determination of apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS.

Coward L, Gorman G, Noker P, Kerstner-Wood C, Pellecchia M, Reed JC, Jia L.

J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6. Epub 2006 Jul 21.

PMID:
16859853
21.

Interspecies pharmacokinetics and in vitro metabolism of SQ109.

Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE.

Br J Pharmacol. 2006 Mar;147(5):476-85.

22.

Cerebral microbleeds are common in ischemic stroke but rare in TIA.

Werring DJ, Coward LJ, Losseff NA, Jäger HR, Brown MM.

Neurology. 2005 Dec 27;65(12):1914-8.

PMID:
16380612
23.

Catastrophic primary antiphospholipid syndrome presenting as status epilepticus.

Coward LJ, Kullmann DM, Hirsch NP, Howard RS, Lucas SB.

J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1607-8. No abstract available.

24.

Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.

Jia L, Coward L, Gorman GS, Noker PE, Tomaszewski JE.

J Pharmacol Exp Ther. 2005 Nov;315(2):905-11. Epub 2005 Aug 5.

PMID:
16085758
25.

Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis.

Coward LJ, Featherstone RL, Brown MM.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000516. Review.

PMID:
15846607
26.
27.

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.

Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M.

Br J Pharmacol. 2005 Jan;144(1):80-7.

28.

Carotid artery stenting with and without cerebral protection.

Brown MM, Featherstone RL, Coward LJ.

Stroke. 2004 Nov;35(11):2434-5. Epub 2004 Sep 9. No abstract available.

PMID:
15359069
29.

Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI.

Werring DJ, Frazer DW, Coward LJ, Losseff NA, Watt H, Cipolotti L, Brown MM, Jäger HR.

Brain. 2004 Oct;127(Pt 10):2265-75. Epub 2004 Jul 28.

PMID:
15282216
30.

Modification of Cytochrome c by 4-hydroxy- 2-nonenal: evidence for histidine, lysine, and arginine-aldehyde adducts.

Isom AL, Barnes S, Wilson L, Kirk M, Coward L, Darley-Usmar V.

J Am Soc Mass Spectrom. 2004 Aug;15(8):1136-47.

31.

International carotid stenting study: protocol for a randomised clinical trial comparing carotid stenting with endarterectomy in symptomatic carotid artery stenosis.

Featherstone RL, Brown MM, Coward LJ; ICSS Investigators.

Cerebrovasc Dis. 2004;18(1):69-74. Epub 2004 Jun 1.

PMID:
15178990
32.

Criteria for an effective theory of consciousness and some preliminary attempts.

Coward LA, Sun R.

Conscious Cogn. 2004 Jun;13(2):268-301. Review.

PMID:
15134761
33.

Percutaneous transluminal angioplasty and stenting for carotid artery stenosis.

Coward LJ, Featherstone RL, Brown MM.

Cochrane Database Syst Rev. 2004;(2):CD000515. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD000515.

PMID:
15106153
34.

Brain stem encephalitis caused by primary herpes simplex 2 infection in a young woman.

Tang JW, Coward LJ, Davies NW, Geretti AM, Howard RS, Hirsch NP, Ward KN.

J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1323-5.

35.

Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization.

Aslan M, Ryan TM, Townes TM, Coward L, Kirk MC, Barnes S, Alexander CB, Rosenfeld SS, Freeman BA.

J Biol Chem. 2003 Feb 7;278(6):4194-204. Epub 2002 Oct 24.

36.

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.

Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S.

Lancet. 2002 Aug 31;360(9334):671-7.

PMID:
12241873
37.

High throughput two-dimensional blue-native electrophoresis: a tool for functional proteomics of mitochondria and signaling complexes.

Brookes PS, Pinner A, Ramachandran A, Coward L, Barnes S, Kim H, Darley-Usmar VM.

Proteomics. 2002 Aug;2(8):969-77.

PMID:
12203892
38.

HPLC-mass spectrometry of isoflavonoids in soy and the American groundnut, Apios americana.

Barnes S, Wang CC, Kirk M, Smith-Johnson M, Coward L, Barnes NC, Vance G, Boersma B.

Adv Exp Med Biol. 2002;505:77-88. No abstract available.

PMID:
12083468
39.

Developmental lessons of seasoned marital and family therapists: a qualitative investigation.

Protinsky H, Coward L.

J Marital Fam Ther. 2001 Jul;27(3):375-84.

PMID:
11436429
40.

Heterogeneity of O-glycosylation in the hinge region of human IgA1.

Novak J, Tomana M, Kilian M, Coward L, Kulhavy R, Barnes S, Mestecky J.

Mol Immunol. 2000 Dec;37(17):1047-56.

PMID:
11399322
41.

Hydrogen-deuterium exchange as a probe of folding and assembly in viral capsids.

Tuma R, Coward LU, Kirk MC, Barnes S, Prevelige PE Jr.

J Mol Biol. 2001 Feb 23;306(3):389-96.

PMID:
11178899
42.

Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States).

Horn-Ross PL, Barnes S, Lee M, Coward L, Mandel JE, Koo J, John EM, Smith M.

Cancer Causes Control. 2000 Apr;11(4):289-98.

PMID:
10843440
43.

p-Cresol sulfate is the dominant component of urinary myelin basic protein like material.

Cao L, Kirk MC, Coward LU, Jackson P, Whitaker JN.

Arch Biochem Biophys. 2000 May 1;377(1):9-21.

PMID:
10775436
44.

Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci.

Safavy A, Khazaeli MB, Kirk M, Coward L, Buchsbaum DJ.

Bioconjug Chem. 1999 Jan-Feb;10(1):18-23.

PMID:
9893959
45.

Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat.

Fritz WA, Coward L, Wang J, Lamartiniere CA.

Carcinogenesis. 1998 Dec;19(12):2151-8.

PMID:
9886571
46.

Metabolism of the isoflavones genistein and biochanin A in human breast cancer cell lines.

Peterson TG, Ji GP, Kirk M, Coward L, Falany CN, Barnes S.

Am J Clin Nutr. 1998 Dec;68(6 Suppl):1505S-1511S. doi: 10.1093/ajcn/68.6.1505S.

PMID:
9848525
47.

Chemical modification of isoflavones in soyfoods during cooking and processing.

Coward L, Smith M, Kirk M, Barnes S.

Am J Clin Nutr. 1998 Dec;68(6 Suppl):1486S-1491S. doi: 10.1093/ajcn/68.6.1486S.

PMID:
9848521
48.

Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate.

Dalu A, Haskell JF, Coward L, Lamartiniere CA.

Prostate. 1998 Sep 15;37(1):36-43.

PMID:
9721067
49.

HPLC-mass spectrometry analysis of isoflavones.

Barnes S, Coward L, Kirk M, Sfakianos J.

Proc Soc Exp Biol Med. 1998 Mar;217(3):254-62.

PMID:
9492333
50.

Intestinal uptake and biliary excretion of the isoflavone genistein in rats.

Sfakianos J, Coward L, Kirk M, Barnes S.

J Nutr. 1997 Jul;127(7):1260-8.

PMID:
9202077

Supplemental Content

Loading ...
Support Center